• Semaphorin Receptors Antagonize Wnt Signaling

  2026-08-13

  This preprint identifies Neuropilin and Plexin semaphorin receptors as previously unrecognized antagonists of Wnt signaling, acting downstream of Dishevelled to promote proteasome-dependent β-catenin destabilization. Its receptor-specific results provide a framework for separating GSK3/CK1-dependent regulation from broader pathway effects when designing Wnt-focused cell assays.

• U-73122: From PLC Signaling to Translational Insight

  2026-08-13

  U-73122 offers a practical way to interrogate phospholipase C-dependent calcium signaling, chemotaxis, inflammation, and cancer-cell invasion. This thought-leadership guide connects mechanism, assay design, evidence boundaries, and translational strategy without treating pharmacological inhibition as a substitute for pathway validation.

• IDO1 Inhibition Activates Tumor-intrinsic STAT3

  2026-08-12

  This study uses single-cell RNA sequencing to show that apo-IDO1 inhibition can activate antitumor immune cells while simultaneously inducing an IL-6–JAK2/STAT3 survival program in tumor cells. The findings provide a mechanistic rationale for combining IDO1-directed treatment with pathway-level JAK2/STAT3 inhibition, while also emphasizing the limits of translating immune activation into therapeutic benefit.

• Belinostat: Reading HDAC Response Beyond Viability

  2026-08-12

  Belinostat (PXD101) can produce both growth arrest and tumor-cell killing, making a single viability endpoint difficult to interpret. This guide presents a phenotype-centered assay framework for connecting histone deacetylase inhibition with cell-cycle, death, and translational readouts.

• SNAI1–PIK3R2/p-EphA2 Signaling in Thymic Tumors

  2026-08-11

  This 2024 study identifies SNAI1 as an oncogenic hub that links epithelial–mesenchymal transition, cancer stem cell-like traits, and macrophage remodeling in thymic epithelial tumors. Multi-omics, functional, single-cell, and biochemical analyses support a SNAI1–PIK3R2/p-EphA2–GSK3β/β-catenin signaling model and suggest that SNAI1 inhibition merits further investigation in thymic carcinoma.

• Dasatinib (BMS-354825) in Cancer Research

  2026-08-11

  Dasatinib (BMS-354825) enables pathway-focused studies of Src, Bcr-Abl, FAK, cell-cycle control, and metastatic behavior across cancer models. This practical guide connects validated product performance with assay design, the SNAI1–PIK3R2/p-EphA2 findings in thymic epithelial tumors, and troubleshooting strategies that separate target engagement from nonspecific toxicity.

• Catalpol in Alzheimer’s Disease: Mechanisms and Evidence

  2026-08-10

  The 2022 review by Chen et al. synthesizes evidence that catalpol, an iridoid glycoside from Rehmannia glutinosa, may protect against Alzheimer’s disease through antioxidant, anti-inflammatory, antiapoptotic, and broader neuroprotective actions. Its main value is mechanistic integration across interconnected pathological processes, while its translational conclusions remain limited by the heterogeneity of the underlying preclinical studies.

• MOF Nanoparticles for Non-Invasive Epilepsy Therapy

  2026-08-09

  The reference study presents ultrasound-activated piezoelectric nanoparticles built on a metal-organic framework to cross the blood–brain barrier and modulate epileptic neural activity without implanted electrodes. By combining brain-targeting ligands with platinum nanoclusters, the platform is designed to integrate neuromodulation, transport, and regulation of oxidative and inflammatory stress.

• Palonosetron Hydrochloride in 5-HT3 Assays

  2026-08-08

  Palonosetron hydrochloride combines subnanomolar 5-HT3 receptor activity with a practical route into transporter interaction studies. This workflow-focused guide covers receptor assays, OCT2/MATE1 profiling, assay controls, and troubleshooting for cancer research.

• Diuron: Mechanistic Insights and Strategic Guidance for Tran

  2026-08-07

  This article examines Diuron (3-(3,4-dichlorophenyl)-1,1-dimethylurea) as a dual-use tool in plant biology and translational toxicology, integrating recent mechanistic discoveries with strategic workflow recommendations for researchers. Drawing on network toxicology, experimental validation, and APExBIO’s high-purity product, we explore the compound’s herbicidal action, nephrotoxicity, and environmental implications, offering a forward-looking perspective on risk assessment and experimental design.

• Dual-Action p38α Inhibitors Enhance Dephosphorylation Dynami

  2026-08-06

  This study uncovers a novel mechanism by which certain p38α MAP kinase inhibitors, including JNJ-3026582 (RWJ 67657), both block kinase activity and accelerate phosphatase-mediated dephosphorylation of the activation loop. These findings suggest new strategies to improve specificity and efficacy in targeting p38 MAP kinase signaling for inflammatory disease research.

• Neutrophil Extracellular Traps in CML: Differential TKI Effe

  2026-08-06

  This study reveals that neutrophil extracellular trap (NET) formation is elevated in chronic myeloid leukemia (CML), and that tyrosine kinase inhibitors (TKIs) modulate this process in distinct ways. The findings suggest a mechanistic link between TKI therapy, particularly ponatinib, and increased vascular toxicity risk, offering new perspectives for CML pathophysiology and treatment monitoring.

• CD28-ARS2 Axis Regulates PKM2 Splicing for T Cell Metabolic

  2026-08-05

  This study uncovers how the CD28-ARS2 signaling axis drives alternative splicing of pyruvate kinase (PKM) to favor PKM2 in activated CD8+ T cells, endowing them with enhanced metabolic flexibility essential for antitumor immunity. These findings reveal a previously unappreciated, PI3K-independent mechanism of immunometabolic reprogramming with implications for T cell-based cancer therapies.

• Enzymatic Isolation Shapes Colorectal Cancer Organoid Succes

  2026-08-05

  This study systematically compares four enzymatic tissue dissociation methods and demonstrates that Collagenase and Hyaluronidase produce superior colorectal cancer organoid yield and expansion. These findings offer a practical framework for optimizing patient-derived organoid protocols and advancing translational research in cancer modeling.

• Sodium Citrate in Programmable 3D SERS Arrays: Mechanistic I

  2026-08-04

  Explore the pivotal role of sodium citrate as a buffering agent and metal ion chelator in the programmable fabrication of 3D SERS nanocluster arrays. This article delivers a mechanistic deep dive and practical optimization strategies, distinguishing itself with advanced protocol analytics and reference-backed guidance.

16315 records 1/1088 page Next 12345 下5页 Last page